By Kelly Traverso, Life Sciences R&D, Deloitte Consulting LLP


This week's blog, by Kelly Traverso from the US firm, first appeared on the US Center for Health Solutions blog site. The blog looks at how utilising automation can help transform pharmacovigilance.

Sometimes a relatively small investment can lead to the development of a product or process that benefits a company, an industry, or even society as a whole. The three-point seat belt, for example, is a simple strap of nylon webbing that protects drivers and passengers from being injured in an accident. This innovation helped to transform safety standards in the automotive industry and has saved millions of lives.1

Similarly, the pharmaceutical industry is focused on ensuring the safety of its customers and the effectiveness of its products. Drug manufacturers use numerous pharmacovigilance (PV) processes and systems to make sure their portfolio complies with government safety standards. PV is the practice of monitoring the effects of a drug after its release to identify previously unreported adverse reactions.

Some manufacturers are taking PV to the next level by making modest investments to automate processes. This can help drug makers draw new insights from safety data to reduce PV costs, improve product efficacy, and discover new combinations and cures that—like the three-point seat belt—could benefit their company, the pharma industry, and society.

Automation could improve case processing and signaling

Numerous industry and marketplace trends are challenging existing PV systems and processes,2 driving some pharma companies to consider more efficient and cost-effective ways to produce robust safety data and mine it for high-quality information. Deloitte recently surveyed senior executives from mid- and large-cap life sciences companies that have global portfolios of innovative therapies. We wanted to learn more about the industry’s PV practices and find out what they expect for the future. For example, some survey respondents said they are using (or considering) automation to help reduce case-processing costs and improve signaling. Here’s a closer look:

Case processing: Driving cost out of case processing was cited as the primary goal among 90 percent of our survey respondents. Case processing can account for 40 percent to 85 percent of PV budgets. Moreover, case volumes are growing at a rate of 10-15 percent per year.3 Some manufacturers are outsourcing, taking advantage of scale, and moving aggressively to automate case processing. Survey respondents expect automation could lead to an average annual cost savings of 30 percent per Individual Case Safety Report (ICSR).

Gaining cost control over case processing, while maintaining compliance and enhancing patient safety, depends on a company’s ability to automate more of these activities. Investments into automation can increase the productivity of case-processing teams significantly. At scale, the range can be as much as 300 or 400 annual ICSRs per full-time equivalent, to 1,000 or 2,000 ICSRs per FTE. Among productivity drivers are native automation and “bolt-on” tools that can reduce the effort required to perform duplicate checks, speed up coding activities, and streamline narrative writing. However, there is limited capability to automate away entire stages within case-processing (as opposed to discrete sub-parts within stages). Further, end-to-end case automation, even for relatively simple cases, is even further from a functioning production capability, despite a number of proofs of concept being tested.

Signaling: Survey respondents see a broad range of opportunities to improve their signal processing and investigation maturity. Half of respondents say they plan to expand these capabilities. As pharma companies drive toward true safety management, short-term signaling investments are likely to focus on visualization and longer-term efforts related to data integration as well as tool and process improvements. Using safety information to tie back into the discovery process remains a gap due to limitations with existing signal detection and management systems. The better the data quality and consistency, the better the signal detection. The ultimate goal is predictive signaling.

Automation in action

Later this summer, Deloitte will release a publication that examines why and how pharma companies are investing in automation and advanced analytics. We will show how they can gain process efficiencies, free-up resources to perform higher-value activities (e.g., benefits-risk evaluation and management, signal investigation, and real-world evidence analysis), improve quality assurance, and maximize return on their PV investment. The paper also will show that even greater gains are possible if companies buckle up and expand their technology and analytics use to create a PV system that focuses on benefit/risk management and proactive surveillance across the entire product lifecycle. Like the three-point seat belt, this approach may benefit pharma companies, the life sciences industry, and society as a whole.


Kelly Traverso - Specialist Leader, Deloitte Consulting LLP

Kelly Traverso is a Specialist Leader in the Deloitte Consulting LLP’s Life Sciences and Health Care practice. She has extensive Drug Safety, concentrating in the areas of Drug Safety Operations and training.

Email | LinkedIn




Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.


Post a comment

Comments are moderated, and will not appear until the author has approved them.